Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Ashraf Taye* and Ihab T. Abdel-Raheem**

* Departments of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, Egypt.
** Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.

ABSTRACT

Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is unknown. Material and methods. The present study was conducted to investigate effect of eplerenone against liver injury induced by carbon tetrachloride (CCl₄) in rats. The biochemical liver function tests and oxidative stress parameters including malondialdehyde (MDA), reactive oxygen species (ROS), in addition to the reduced glutathione (GSH) levels were evaluated. Moreover, serum tumor necrotic factors (TNF-α) level and histopathological changes were examined. Results. Our results show that pre-treatment with eplerenone (4 mg/kg per day for 4 weeks) revealed attenuation in serum activities of alanine aminotransferase (ALT), aspartate aminotransferase, (AST), alkaline phosphatase (ALP) and bilirubin levels that were enhanced by CCl₄. Further, pre-treatment with eplerenone inhibited the elevated hepatic MDA content and restored hepatic GSH to its normal level. The enhanced hepatic ROS production in CCl₄-treated group was markedly decreased by eplerenone administration. Eplerenone pre-treatment significantly attenuated the inflammatory responses caused by CCl₄ as evident by the decreased serum TNF-α level. Histopathological studies showed that eplerenone alleviated the liver damage and reduced the lesions caused by CCl₄. Conclusion. Collectively, the present study provides a proof to hepatoprotective actions of eplerenone via reducing oxidative stress and inflammatory responses in CCl₄-induced liver damage in rat model.

Key words. Eplerenone. Liver injury. Oxidative stress. TNF-α.

INTRODUCTION

Aldosterone is the main effector peptides of the renin-angiotensin-aldosterone system and is known to play an important role in the development of hepatic fibrosis and portal hypertension.¹-³ Aldosterone can promote tissue inflammation and fibrosis and plays a crucial role in cell proliferation and apoptosis.⁴-⁶ In addition, oxidative stress and pro-inflammatory cytokines play essential roles in the development of cholestatic liver injury.⁷ It has been reported that induction of oxidative stress and mineralocorticoid receptor (MR)-dependent transcription of proinflammatory genes are some of the mechanisms account for the injurious effects of aldosterone.⁸-¹⁰ Accumulating evidences indicate that MR also mediates inflammation and fibrosis through the proinflammatory transcription factor NF-κB activation in liver, heart, and glomerular mesangial cells.¹¹-¹³ Although several reports stated that angiotensin II type 1 receptor blockers and angiotensin-converting enzyme inhibitors have been reported to prevent the development of hepatic fibrosis in numerous animal¹⁴,¹⁵ and human,¹⁶-¹⁸ little is known regarding role of aldosterone antagonist in liver injury.

Additionally, the results arising from these studies have shown to be controversial.²,¹⁹,²⁰ While one report demonstrated that spironolactone prevented pig serum-induced hepatic fibrosis in rats,² another study showed that spironolactone did not produce any anti-fibrotic effects during bile duct ligation-induced hepatic fibrosis.²⁰
On the other hand, eplerenone has been shown to reveal a high specificity for MR. Several reports demonstrated the efficacy and safety of eplerenone in the treatment of hypertension. However, there is scanty information concerning both effect of eplerenone on liver injury and the mechanism(s) involved in this effect. The preventive action of CCl₄-induced liver damage has been widely used as an indicator of liver protective activity of drugs. Therefore, the present study was undertaken to examine effect of eplerenone on liver injury induced by CCl₄ in rat model and underline its mechanism(s) in this setting.

**MATERIAL AND METHODS**

**Drugs and chemicals**

Eplerenone, Lucigenin, NADPH oxidase and SOD (Sigma-Aldrich, St. Louis, MO, USA); TNF-α kit (Koma Biotech. Inc., Korea); Carbon tetrachloride (BDH Chemicals, England). All other chemicals are of analytical grade.

**Animals**

Adult male Sprague-Dawley rats (150–180 g) were used throughout the experiments. Rats were fed a standard diet of commercial rat chow and tap water *ad libitum* and left to acclimatize to the environment for at least one week prior to inclusion in the experiments. Experiments were conducted in accordance with the guidelines for animal care of the United States Naval Medical Research Centre, Unit No. 3, Abbaseya, Cairo, Egypt.

The animals were divided into 4 groups each of 8 rats:

- **Group 1.** Rats of this group were injected with normal saline, intraperitoneally and served as a control.
- **Group 2.** Rats were treated with (4.0 mg/kg, orally) of eplerenone for 4 weeks.
- **Group 3.** Hepatotoxicity was induced in rats of this group by administration of CCl₄ (1 mL/kg ip; diluted 1:4 in olive oil; twice per week for 4 weeks).
- **Group 4.** Rats were pretreated with (4.0 mg/kg, orally, 4 week) of eplerenone 1 h before CCl₄ (1 mL/kg, ip) administration.

After 4 weeks, blood samples were collected via cardiac puncture from the rats under anesthesia.

Then the rats were sacrificed by decapitation and liver tissues were isolated. The blood samples were centrifuged at 5,000 g for 10 min, and serum samples were collected for biochemical tests. All liver tissues were immediately dissected out and immediately dipped into liquid nitrogen. Other liver tissues were fixed in 10% neutral buffered formalin for subsequent sectioning and mounting on microscope slides. The remaining liver tissue and serum samples were stored at -80 °C until studied for other parameters. Thereafter, the liver tissues were homogenized in 0.25 M sucrose, 10 mM Tris-HCl, 1 mM EDTA medium, pH 7.4, centrifuged at 10,000 g for 10 min and supernatants used for biochemical analysis. Total protein concentration was determined using a bicinchoninic acid (BCA) protein assay kit (Pierce Chemicals, USA).

**Assessment of serum aminotransferases, alkaline phosphatase and bilirubin**

Liver function tests in the serum such as AST, ALT were determined according to the method described by Reitman and Frankel. Serum ALP was determined according to the method of Eaton RH using colorimetric kit obtained from Diamond Co., Egypt. Total or direct serum bilirubin was determined spectrophotometrically according to the method of Merino, *et al.* using kits purchased from Randox, Laboratory. Ltd., UK.

**Determination of hepatic malondialdehyde and GSH levels**

Lipid peroxidation was determined in liver homogenates as thiobarbituric acid reactive species (TBARS; sometimes referred to as MDA as a marker of oxidative stress according to the method described by Buege and Aust). Additionally, hepatic GSH was determined spectrophotometrically at 412 nm. Hepatic GSH values were expressed as nmol/mg protein.

**Measurement of ROS production in liver homogenates**

ROS production of liver homogenates were measured using lucigenin-enhanced chemiluminescence assay. Briefly, liver homogenates were resuspended (100 µg protein/well) in modified HEPES buffer containing (mM) NaCl 140, KCl 5, MgCl₂ 0.8, CaCl₂ 1.8, Na₄HPO₄ 1, HEPES and 1% glucose, pH 7.4. Immediately before recording chemiluminescence, NADPH (final concentration 100 µM) was added and dark-adapted lucigenin (5 µM) was added via an auto-dispenser. Light emission was recorded using a
As major criteria for liver dysfunction, serum ALT and AST, ALP total and direct bilirubin levels in the serum of rats treated with CCl₄ were found to be significantly higher than control. CCl₄ produced dramatic changes in these parameters. However, pre-treatment with eplerenone reduced these values significantly compared to that of the control group (Table 1).

### RESULTS

#### Biochemical serum parameters (ALT, AST, ALP and bilirubin)

Biochemical results of serum ALT, AST, ALP, total and direct bilirubins are summarized in table 1.

<table>
<thead>
<tr>
<th>Group/parameters</th>
<th>ALT (IU/L)</th>
<th>AST (IU/L)</th>
<th>ALP (IU/L)</th>
<th>Total-bilirubin (µmol/L)</th>
<th>Direct-bilirubin (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>41 ± 3.8</td>
<td>102 ± 9</td>
<td>200 ± 12</td>
<td>0.65 ± 0.05</td>
<td>0.25 ± 0.01</td>
</tr>
<tr>
<td>Eplerenone</td>
<td>50 ± 4.3</td>
<td>115 ± 10</td>
<td>222 ± 15</td>
<td>0.74 ± 0.01</td>
<td>0.30 ± 0.02</td>
</tr>
<tr>
<td>CCl₄</td>
<td>190 ± 10**</td>
<td>320 ± 22**</td>
<td>334 ± 24**</td>
<td>2.10 ± 0.09**</td>
<td>0.71 ± 0.03 *</td>
</tr>
<tr>
<td>Eplerenone + CCl₄</td>
<td>70 ± 4.5*</td>
<td>150 ± 8*</td>
<td>257 ± 14*</td>
<td>0.92 ± 0.04</td>
<td>0.35 ± 0.01*</td>
</tr>
</tbody>
</table>

Each value represents the mean ± SEM. (n = 7-9/group). Data comparison was performed using ANOVA followed by Bonferroni’s test. *P < 0.05; **P < 0.01; compared with the initial value of control; *P < 0.05 compared with CCl₄ group as indicated.

---

**Figure 1.** Hepatic MDA levels in the study groups: control and CCl₄-treated groups, in the absence or presence of eplerenone. Values of each bar represent the mean ± SEM. The hepatic MDA contents were significantly increased following to CCl₄ treatment (P < 0.05) and pre-treatment of rats with eplerenone significantly (P < 0.05) decreased these levels to that of control, *p < 0.05 compared with control value.

In addition, CCl₄ showed a significant decrease in the hepatic GSH levels; however, eplerenone restored GSH almost to its control level (Figure 2).

Figure 2. Hepatic GSH content determination: control and CCl₄-treated groups, in the absence or presence of eplerenone. Values of each bar represent the mean ± SEM. CCl₄ showed a significant decrease in the hepatic GSH levels and eplerenone restored GSH almost to its control level.

In a separate experiment tissue homogenates were incubated with SOD (200 U/mL) for the indicated time, and the signal was completely inhibited.

Figure 3. ROS production assessment: control and CCl₄-treated groups, in the absence or presence of eplerenone. Values of each bar represent the mean ± SEM. ROS production measured by lucigenin-enhanced chemiluminescence (5 µM) and expressed as arbitrary light unit (percentage of control). ROS production was markedly increased following to CCl₄ treatment and eplerenone as well as apocynin inhibited this enhanced ROS generation.

Histopathological examination

Hematoxylin and eosin histological slides were evaluated by a blinded investigator and analyzed using a semi-quantitative score for inflammation. In control group, there were no pathological changes in healthy control livers which showed normal lobu-
lar architecture with central vein and radiating hepatic cords (Figure 5).

The histological examination of the liver showed distorted architecture with distorted central vein and multifocal areas of coagulative necrosis along the hepatic parenchyma in CCl4-treated group. The lesions in the liver of CCl4 group pre-treated with eplerenone were attenuated except for congestion of some portal blood vessels, and few cells with vacuolated cytoplasm.

**DISCUSSION**

CCl4 has been widely used to induce experimental hepatic damage as it induces liver cell necrosis and apoptosis, and can be used to induce hepatic fibrosis or cirrhosis by its repetitive administration.33 We verified the hepatotoxicity of CCl4 by the increased serum aminotransferases and decreased albumin levels compared to that of the control group. Raised serum enzyme levels in CCl4-injected rats can be attributed to the damaged hepatocellular structural integrity.34 Here, we try to investigate the relevance of using the MR antagonist, eplerenone in hepatoprotection of CCl4-induced liver injury and the underlying mechanism of this protection. Of interest, eplerenone administration not only restored the serum aminotransferases to that of control levels but also the serum albumin level as well.

It is noteworthy that oxidative stress and lipid peroxidation mediated by oxygen free radicals has been implicated as a common link between chronic liver damage and hepatic fibrosis.35 Reactive oxygen metabolites are shown to mediate microvascular disturbances by various chemical substances.36

During the initial phase of CCl4 toxicity following its administration, a large amount of CCl4 is converted to trichloromethyl radical or other radicals, which in turn accelerate several metabolic pathways.37 These radicals appear to affect the adjacent lipids in the tissues and induce lipid peroxidation.

Hepatocytes are well recognized as being continuously exposed to ROS in various liver diseases including cholestasis. Antioxidant molecules such as GSH and anti-oxidative enzymes such as SOD, and catalase, ordinarily provide hepatocytes with resistance to oxidative stresses.38 In the present study, administration of CCl4 resulted in marked elevation of oxidative stress markers as evident by increased lipid peroxidation product MDA, ROS production and reduction in antioxidant molecule contents such as GSH. These findings suggest that oxidative stress reactions might be an important contributing factor for the CCl4-induced liver dysfunction. It is well established that oxidative stress and lipid pe-
roxidation are involved in the pathogenesis of liver injury.\(^39\)

On the other hand, aldosterone can increase oxidative stress by both increasing ROS production and reducing ROS scavenging capacity of the cells.\(^40\)

A reduction in antioxidant capacity can also participate in the increase in oxidative stress induced by aldosterone since we have observed that eplerenone is able to increase glutathione levels in hypertensive rats, the most important systemic antioxidant agent.\(^41\) Interestingly, the current study revealed that eplerenone was able to normalize the elevated biochemical oxidative stress markers, ROS production and restore GSH normal level that plays an important role in the antioxidant defence mechanism in liver of CCl\(_4\)-treated rats, suggesting antioxidant properties of eplerenone. Hence, the hepatoprotective effect of eplerenone appears to be due to the suppression of oxidative stress and lipid peroxidation.

Recently, it has been demonstrated that spironolactone decreased aldosterone-induced oxidative stress via activation NADPH oxidase enzyme as a major source of ROS thereby reducing cardio-vascular-renal damage.\(^42\) According to this concept, an eligible explanation to the inhibitory effect of eplerenone on ROS production may be, at least, owing to inhibition of NADPH oxidase enzyme. This assumption is evident by the ability of the NADPH oxidase inhibitor, apocynin to inhibit ROS generation -induced by CCl\(_4\) in liver homogenates.

An increasing number of evidence indicates that activation of the MR has been implicated in mediating the inflammation observed in vessels, heart and renal cortex of rodent models of diabetes and hypertension.\(^43-45\) MR blockages reduced expression of pro-inflammatory and pro-thrombotic factors in adipose tissue and increased expression of adiponectin in heart and adipose tissue of obese, diabetic mice.\(^46\) Moreover, administration of spironolactone attenuated TNF-\(\alpha\) level in chronic constriction injury may be due to its anti-inflammatory properties.\(^47\) Further, it has been reported that the central administration of spironolactone prevented the rise in TNF-\(\alpha\) in the heart failure model.\(^48\) Because TNF-\(\alpha\) appears early in the cytokine cascade,\(^49\) it has been suggested that other proinflammatory cytokines might also be reduced. Data from the present study support that concept we have shown that pretreatment with eplerenone to CCl\(_4\)-induced liver injury group abrogated TNF-\(\alpha\) level. This effect may be accounted for the anti-inflammatory properties of eplerenone. The present study demonstrates a potential role of MR blockage in attenuation of the inflammatory process. This role is supported by the fact that the administration of MR antagonist reduced atherosclerotic lesion in different models of atherosclerosis.\(^50-52\) This reduction in atherosclerotic process was accompanied by a reduction of inflammatory markers.\(^51,52\)

Noteworthy, the histopathological findings complemented the results of CCl\(_4\) on the liver as evident by the hepatic necrosis, diffuse fatty changes, portal fibrosis and mononuclear cell infiltration. Such lesions were induced via the formation of free radicals, especially the ROS. Importantly, the damaging effects of CCl\(_4\) were subsided and attenuated on pretreatment with eplerenone. Thus, anti-oxidative stress and anti-inflammatory properties of eplerenone appears to play a key role in the attenuation of inflammation, and then preserve the structural integrity of the hepatocellular membrane resulting in amelioration of liver enzyme functions such asaminotransferases and ALP.

**CONCLUSION**

In conclusion, the present study demonstrated a potential protective effect of MR antagonist, eplerenone in liver injury-induced by CCl\(_4\). The corresponding mechanisms of this protection may be mediated via anti-inflammatory and anti-oxidative stress properties of MR blockage by eplerenone. Thus, eplerenone might have promising beneficial anti-oxidative and anti-inflammatory effects thereby protecting against liver damage. Nevertheless, larger prospective clinical studies to determine the therapeutic effects of eplerenone in liver injury may be warranted.

**ACKNOWLEDGMENT**

We are grateful to Prof. Kawkaab A. Abd elaziz, Department of Pathology, Faculty of Veterinary Medicine, Cairo University for her kind help in performing histopathological studies and interpretation of the results.

**REFERENCES**


